Swimmer’s ear: ALK gains exclusive rights to market OTIPRIO in U.S.
by Press Release from Outbreak News Today on (#54RR9)
ALK, a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, for the co-promotion of OTIPRIO(R) (ciprofloxacin otic suspension) for acute otitis externa (AOE) in the U.S. in patients six [...]
The post Swimmer's ear: ALK gains exclusive rights to market OTIPRIO in U.S. appeared first on Outbreak News Today.